AstraZeneca
First for Japan with the approval of AstraZeneca’s Lokelma in hyperkalaemia
March 26, 2020Sales and Marketing AstraZeneca, Astra|Zeneca, Japan, Lokelma, hyperkalaemia, pharma
Japan’s Ministry of Health, Labour and Welfare has awarded approval to AstraZeneca’s Lokelma for the treatment of hyerkalaemia, marking the …
AstraZeneca to leverage Silence Therapeutics’ siRNA expertise in $480mn deal
March 25, 2020Research and Development, Sales and Marketing AstraZeneca, Silence Therapeutics, collaboration, pharma
Silence Therapeutics has revealed it has struck a new collaboration with AstraZeneca which will trigger the “acceleration and re-prioritisation of …
Japan grants orphan drug designation to Lynparza for BRCA+ unresectable pancreatic cancer
March 19, 2020Research and Development, Sales and Marketing AstraZeneca, Japan, lynparza, pharma
AstraZeneca has confirmed that its PARP inhibitor Lynparza (olaparib) has been awarded orphan drug designation in Japan for the maintenance …
Success and failure at Phase 3 for AstraZeneca’s Imfinzi combos in first-line small cell lung cancer
March 17, 2020Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, pharma
AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …
AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer
March 13, 2020Medical Communications, Research and Development AstraZeneca, cediranib, lynparza, pharma, trial failure
Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined …
Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer
March 6, 2020Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …
Galecto hires new Chief Medical Officer
February 7, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Galecto
Galecto has announced Bertil Lindmark as their new Chief Medical Officer. He began his posting on 1 February 2020.Lindmark joins …
Insider Interview: Reducing the risk of adverse cardiovascular events
February 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Insider Interview, cardiovascular, heart disease, pharma
Rodrigo Gribble, Vice President Cardiovascular at AstraZeneca, breaks down recently published data from the PEGASUS trial of ticagrelor, a potential …
No NICE recommendation for AstraZeneca’s Tagrisso in EGFR+ lung cancer
January 22, 2020Research and Development, Sales and Marketing AstraZeneca, NICE, Tagrisso, pharma
AstraZeneca’s Tagrisso (osimertinib) has been knocked back for routine use on the NHS in England and Wales by the drug …
Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer
January 16, 2020Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza
It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …
AstraZeneca to discontinue trial for heart disease drug Epanova
January 13, 2020Sales and Marketing AstraZeneca, Phase II Trial, Phase III trial, heart disease, triglycerides
AstraZeneca expects a $100 million writedown for its heart disease drug Epanova, as it discontinues its late stage trial. This …
FDA gives a priority review for key heart failure drug Farxiga
January 6, 2020Sales and Marketing AstraZeneca, Heart Failures, farxiga
The FDA has accepted a New Drug Application (sNDA) and has granted a priority review for AstraZeneca’s drug Farxiga (dapagliflozin) …
AstraZeneca’s drug Lokelma approved in China
January 6, 2020Sales and Marketing AstraZeneca, China, FDA, eu commission, kidney failure, potassium
AstraZeneca’s Lokelma has been approved by the National Medical Products Administration in China. This is due to positive results based …
AstraZeneca’s triple combination therapy for patients with COPD approved in China
December 23, 2019Sales and Marketing AstraZeneca, COPD, China, respiration
AstraZeneca has announced that budesonide-glycopyrroniunm-formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease …
FDA gives accelerated approval to AstraZeneca and Daiichi’s breast cancer drug
December 23, 2019Sales and Marketing AstraZeneca, Breast Cancer drug, Cancer, breast cancer, skin cancer
The FDA has approved the breast cancer drug Enhertu, developed by AstraZeneca and Daiichi Sankyo. José Basel, the Executive Vice …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
